Health Canada open data (page 50)
Health Canada publishes 2,987 open datasets on CanQuery: 58 with live tables. Preview tables, export CSV and follow original downloads.
- Datasets
- 2987
- Queryable datasets
- 58
- Mappable datasets
- 0
Datasets
- Drug and vaccine authorizations for COVID-19: List of applications received
- Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications
- Access Consortium statement on COVID-19 vaccines evidence
- ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic
- Interim guide on isopropyl alcohol for use in alcohol-based hand sanitizers and disinfectants: Overview
- Interim guide on isopropyl alcohol for use in alcohol-based hand sanitizers and disinfectants: Quality requirements
- Interim guide on isopropyl alcohol for use in alcohol-based hand sanitizers and disinfectants: Compliance and enforcement
- Coronavirus disease (COVID-19) and food safety
- COVID-19 Food labelling support measures
- COVID-19 Treatments
- Authorized medical devices for uses related to COVID-19: List of products no longer authorized under IO
- Authorized medical devices for uses related to COVID-19: Overview
- Conducting a COVID-19 drug and vaccine clinical trial
- Conducting a clinical trial for COVID-19 medical devices: List of authorized clinical trials
- Medical devices for COVID-19: Conducting a clinical trial
- Guidance on safety and performance specifications for filtering facepiece respirators (FFRs) during COVID-19: Background
- Medical devices for COVID-19: Conducting a clinical trial
- Testing devices for COVID-19: Serological testing devices
- Health Canada’s regulatory response to COVID-19: Access to health products
- Health Canada’s regulatory response to COVID-19: International engagement
- Notice: Technical requirements for anti-microbial claims for medical masks
- Important regulatory considerations for the supply of medical gowns: Guidance to industry
- Ventilators for patients with COVID-19
- Testing devices for COVID-19: Nucleic acid testing devices
- Testing devices for COVID-19: Point-of-care and self-testing devices
- Testing devices for COVID-19: Overview
- Priority strategies to optimize testing and quarantine at Canada’s borders
- Medical Devices Action Plan: Progress report
- Interim order regulating certain UV radiation-emitting and ozone-generating devices under the Pest Control Products Act: Notice
- Health product advertising incidents related to COVID-19: COVID-19 advertising incidents
- Notice: Release of Draft Guidance Document for Consultation: Comparative Pharmacokinetic Studies for Orally Inhaled Products
- Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences
- Guidance for Industry: Standards for Clinical Trials in Type 2 Diabetes in Canada
- Update: Requirements for Tuberculosis Screening of Healthy Volunteers in Phase I Clinical Trials involving Immunosuppressant Drugs or Drugs with Immunosuppressant Properties
- Completed requests for disclosure of confidential business information under s21.1(3)(c) of the Food and Drugs Act
- Disclosure of confidential business information
- Request for disclosure of confidential business information (CBI)
- Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals
- Guidance Document: Preparation of Clinical Trial Applications for use of Cell Therapy Products in Humans
- Notice: Preparation of Clinical Trial Regulatory Activities in the "Non-eCTD Electronic-Only" Format
- Notice: Implementation of eCTD for clinical trial regulatory activities
- Clinical Trials Manual
- Final Guidance Document Data Requirements for Safety and Effectiveness of Steroid Nasal Products for Use in the Treatment of Allergic Rhinitis for Industry
- Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects
- Guidance Document For Clinical Trial Sponsors: Clinical Trial Applications
- Notice to Stakeholders – Clarification of Requirements Under the Food and Drug Regulations When Conducting Clinical Research With Cannabis
- Draft Guidance for Industry: Preparation of Comparative Bioavailability Information for Drug Submissions in the CTD Format
- Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies
- Notice: Clarification of bioanalytical method validation procedures
- Summary: Guidance Document - Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs